Oral Beclomethasone Dipropionate for the Treatment of Steroid-refractory Gastrointestinal Acute Graft-versus-host Disease.
10.5045/kjh.2009.44.4.304
- Author:
Sung Eun LEE
1
;
Seok LEE
;
Byung Sik CHO
;
Ki Seong EOM
;
Yoo Jin KIM
;
Hee Je KIM
;
Chang Ki MIN
;
Seok Goo CHO
;
Dong Wook KIM
;
Jong Wook LEE
;
Woo Sung MIN
;
Chong Won PARK
;
Chun Choo KIM
Author Information
1. Department of Hematology, Catholic Blood and Marrow Transplantation Center, College of Medicine, The Catholic University of Korea, Seoul, Korea. leeseok@catholic.ac.kr
- Publication Type:Case Report
- Keywords:
Oral beclomethasone dipropionate;
Allogeneic stem cell transplantation;
Gastrointestinal acute graft-versus-host disease
- MeSH:
Adrenal Cortex Hormones;
Adult;
Beclomethasone;
Graft vs Host Disease;
Humans;
Korea;
Precursor Cell Lymphoblastic Leukemia-Lymphoma;
Siblings;
Stem Cell Transplantation;
Transplants
- From:Korean Journal of Hematology
2009;44(4):304-309
- CountryRepublic of Korea
- Language:English
-
Abstract:
Acute graft-versus-host disease (GVHD) is one of the most severe complications following allogeneic stem cell transplantation (SCT), and involvement of the gut has been associated with increased mortality and a poorer response to high-dose systemic corticosteroids. For over a decade, oral beclomethasone dipropionate (BDP) has been studied in the treatment of acute gastrointestinal GVHD, as a monotherapy, or in combination with systemic corticosteroids. Here we report, for the first time in Korea, the efficacy of oral BDP (8 mg/day for 25 days) in 3 adults with acute lymphoblastic leukemia who developed steroid-refractory gastrointestinal GVHD (grade III) after myeloablative conditioning SCT (1 matched sibling transplant, 2 matched unrelated transplants). All patients responded completely to oral BDP treatment. Oral BDP is safe and effective for the control of steroid-refractory acute gastrointestinal GVHD.
